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Abstract
Industrial	 sensitizing	 agents	 (allergens)	 in	 living	 and	working	 environments	 play	 an	
important	role	in	eliciting	type	1	allergic	disorders	including	asthma	and	allergic	rhini‐
tis.	Successful	management	of	allergic	diseases	necessitates	identifying	their	specific	
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1  | BACKGROUND AND OBJEC TIVES
Airborne	allergens	 in	 living	and	working	environments	play	an	 im‐
portant	 role	 in	eliciting	 type	1	allergic	disorders,	 including	asthma	
and	hay	 fever.	Allergies	belong	 to	 the	 so‐called	noncommunicable	
diseases	which	have	dramatically	risen	with	industrialization	and	ur‐
banization	 worldwide.1,2	 Nearly	 600	 asthma‐causing	 occupational	
agents	 have	 been	 identified,	 of	 which	 two	 thirds	 are	 airway	 sen‐
sitizers.3	Every	year	new	allergic	agents	are	 identified	at	 changing	
industrial	 or	 agricultural	 worksites,	 for	 example.4,5	 Some	 of	 these	
agents	 (chemical/biological)	 are	also	general	environmental	pollut‐
ants	which	can	be	passively	transported	by	air	(sometimes	over	long	
distances),	and	often	found	in	homes.	Other	industrial	sensitizers	are	
used	by	consumers,	for	example,	genetically	engineered	enzymes	in	
home	 detergents,	 perfume	 sprays	 or	 used	 for	 food	 processing	 in	
home	kitchens.	All	these	substances	contribute	to	a	long	list	of	new	
sensitizing	agents	of	relevance	for	both	occupational	and	general	en‐
vironmental	medicine	and	public	health.
Asthma,	the	disorder	this	guideline	focuses	on	represents	an	in‐
creasing	global	health	problem	and	is	now	affecting	between	8%‐10%	
of	 the	population.6	The	World	Health	Organization	estimates	 that	
around	 235	 million	 people	 suffer	 from	 asthma	 worldwide.7	 This	
implicates	a	high	socio‐economic	cost	in	terms	of	work	and	school	
absenteeism,	consumption	of	resources	(drugs,	consultations,	hospi‐
talizations),	and	deaths.8	The	increase	in	asthma	figures	is	partly	due	
to	an	improvement	in	diagnostic	techniques,	but	other	factors	such	
as	environmental	pollution	(Figure	1)	are	also	relevant	in	industrial‐
ized	countries.9
Environmental	pollution	 is	 a	growing	public	health	problem	al‐
though	the	exact	mechanisms	by	which	it	can	aggravate	asthma	are	
presently	not	 known.	Also	 less	exposure	 to	microbial	 load	and	di‐
versity	in	both	childhood	and	adulthood	due	to	the	global	increase	
in	 urbanization	 has	 been	 suggested	 to	 contribute	 to	 the	 increase	
in	asthma.10	Rhinitis	 is	approximately	3	times	more	prevalent	than	
asthma	in	the	adult	population;	although	symptoms	and	impairment	
are	generally	less	life	threatening	than	those	in	asthma,	this	disorder	
also	represents	a	highly	relevant	socio‐economic	issue.	It	 is	known	
that	there	exists	a	relationship	between	asthma	and	rhinitis	as	well	
as	with	respiratory	infections.
Current	 research	 is	 aimed	 at	 establishing	 the	 immunological	
pathways	that	determine,	not	only	the	phenotypes	and	endotypes	
of	 these	diseases,11,12	but	also	 the	presence	of	certain	biomarkers	
that	allow	precision	medicine	to	be	performed.13,14	Although	there	
is	agreement	to	distinguish	three	possible	immune	responses	in	the	
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causes	 (ie,	 identify	 the	causative	agent(s)	and	 the	 route	of	contact	 to	allergen:	air‐
borne,	or	skin	contact)	to	avoid	further	exposure.	Identification	of	sensitization	by	a	
sensitive	and	validated	measurement	of	specific	IgE	is	an	important	step	in	the	diagno‐
sis.	However,	only	a	limited	number	of	environmental	and	occupational	allergens	are	
available	on	the	market	for	use	in	sIgE	testing.	Accordingly,	specific	in‐house	testing	
by	individual	diagnostic	and	laboratory	centers	is	often	required.	Currently,	different	
immunological	tests	are	in	use	at	various	diagnostic	centers	that	often	produce	con‐
siderably	divergent	results,	mostly	due	to	lack	of	standardized	allergen	preparation	
and	standardized	procedures	as	well	as	inadequate	quality	control.	Our	review	and	
meta‐analysis	exhibited	satisfactory	performance	of	sIgE	detection	test	for	most	high	
molecular	weight	(HMW)	allergens	with	a	pooled	sensitivity	of	0.74	and	specificity	of	
0.71.	However,	for	low	molecular	weight	(LMW)	allergens,	pooled	sensitivity	is	gener‐
ally	lower	(0.28)	and	specificity	higher	(0.89)	than	for	HMW	tests.	Major	recommen‐
dations	based	on	the	presented	data	include	diagnostic	use	of	sIgE	to	HMW	allergens.	
A	negative	sIgE	result	for	LMW	agents	does	not	exclude	sensitization.	In	addition,	the	
requirements	for	full	transparency	of	the	content	of	allergen	preparations	with	details	
on	standardization	and	quality	control	are	underlined.	Development	of	standard	op‐
erating	procedures	for	in‐house	sIgE	assays,	and	clinical	validation,	centralized	quality	
control	and	audits	are	emphasized.	There	is	also	a	need	for	specialized	laboratories	to	
provide	a	custom	service	for	the	development	of	tests	for	the	measurement	of	puta‐
tive	novel	occupational	allergens	that	are	not	commercially	available.
K E Y W O R D S
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development	of	respiratory	allergies,	such	as	the	type	2	immune	re‐
sponse,	the	non–type	2	immune	response,	and	the	mixed	Th2/Th17	
immune	response,	the	intimate	mechanisms	that	generate	them	are	
still	largely	unknown.	Most	of	the	aforementioned	aspects	also	refer	
to	the	less	frequent	type	1	allergic	dermatitis,	such	as	contact	urti‐
caria	including	protein	contact	urticaria	which	have	to	be	differen‐
tiated	 from	 type	4	allergic	 contact	dermatitis,	 not	 covered	by	 this	
guideline.
The	 diagnostic	 measurement	 of	 specific	 IgE	 (sIgE)	 is	 often	 a	
major	step	in	identifying	the	precise	cause(s)	of	respiratory	allergy.	
However,	 only	 a	 limited	 number	 of	 allergen‐sIgE	 are	 commer‐
cially	available,	especially	in	the	occupational	field.	This	necessitates	
the	 development	 and	 use	 of	 in‐house	 tests	 in	 specialized	 labora‐
tories.	A	further	 limitation	of	sIgE	measurement	 is	the	lack	of	vali‐
dated	preparations	for	many	allergenic	agents.	Currently,	different	
immunological	tests	are	available	on	the	market	and	are	in	use.	The	
manufacturers	of	such	tests,	rarely,	if	at	all,	provide	detailed	data	on	
the	allergen	preparations	used,	standardization	of	the	method,	and	
quality	controls	applied.	The	various	tests	often	differ	considerably	
and	their	results	are	hard	to	compare.	So,	a	major	current	problem	is	
lack	of	transparency	in	commercial	sIgE	tests	and	a	lack	of	generally	
accepted	and	applied	procedures	to	assess	whether	the	sensitivity	
and	specificity	of	these	tests	are	appropriate.
There	is	an	urgent	need	for	an	international	consensus	on	tech‐
nical	standards	and	quality	control	for	allergen	preparation	to	serve	
as	an	important	resource	for	physicians	and	laboratories	in	diagnos‐
tics	 of	 exposure‐related	 type	 1	 respiratory	 allergic	 diseases.	 This	
document	 represents	 international	 practical	 statements	 with	 the	
primary	objective	to	provide	an	overview	on	available	methods	re‐
quired	for	state‐of‐the‐art	clinical	diagnostic	purposes	and	for	mak‐
ing	 recommendations	 for	 clinical	 practice.	 This	 document	 focuses	
on	diagnosis	of	respiratory	allergic	disorders	caused	by	occupational	
and/or	environmental	industrial	agents,	but	may	also	be	applied	to	
related	 skin	 allergic	 disorders.	 The	 recommendations	 include	 ex‐
posure	assessment	and	in‐house	in	vitro	testing	with	commercially	
and	noncommercially	 available	 allergens.	A	 further	 aim	 is	 to	 pres‐
ent	current	evidence	on	sIgE	testing	in	the	diagnostics	of	type	1	al‐
lergic	disorders	with	special	regard	to	allergic	work‐related	asthma	
(WRA)	including	occupational	asthma	(OA,	where	nonoccupational	
agents	 do	 not	 play	 a	 causative	 role)	 and	 allergic	work‐aggravated	
(also	called	allergic	work‐exaggerated	or	work‐exacerbated)	asthma.	
Recommendations	for	clinical	practice	are	formulated.	This	practical	
statement	is	intended	to	provide	guidance	to	clinicians,	public	health	
professionals	as	well	as	others	who	interpret	the	scientific	evidence,	
when	new	outcomes	are	reported	(eg,	policy	makers).
Methodological	details	of	this	practical	guideline	are	given	in	the	
Supporting	information	(see	Supplementary	Methods,	page	S2).
2  | CLINIC AL PIC TURES OF T YPE I 
ALLERGY DUE TO AIRBORNE OR SKIN 
E XPOSURES
Type	1	allergy	due	to	airborne	or	skin	exposures	is	defined	clinically	
as	an	immediate	allergic	response	caused	by	a	product	or	raw	mate‐
rial	(eg,	flour)	that	is	present	in	the	living	or	working	environments.	
For	occupational	allergy,	the	agent	should	be	specific	to	the	work‐
place.	Such	allergies	can	affect	many	target	organs,	including	lower	
airways,	nose,	eyes,	and	skin.	The	corresponding	diseases	are	aller‐
gic	asthma,	allergic	rhinitis,	allergic	conjunctivitis,	allergic	contact	ur‐
ticaria/protein	contact	dermatitis	(details	are	given	in	the	Supporting	
information,	clinical	pictures).
There	 is	evidence	 that	 type	1	allergies	caused	by	 industrial	 al‐
lergens	 (by	 either	 a	 product	 or	 a	 raw	material)	 are	 frequently	 not	
documented	in	the	literature.	Since	these	cases	are	left	either	unrec‐
ognized	or	are	not	published,	the	number	of	causative	agents	may	be	
higher	than	that	currently	found	in	the	list	of	sensitizers.	See	exam‐
ple	in	Supporting	information.
Industrial	products	can	also	cause	allergic	reactions	in	consum‐
ers	(see	Allergen	exposure	assessment	section)	but	these	cases	are	
F I G U R E  1  Asthma	between	
population	discrepancies.	Figure	adapted	
from:	ISAAC	(1998),	Lancet	351:1225‐32
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rather	 seldom	described	and	presumably	 rare.	 Ingredients	 such	as	
enzymes	in	fragrances,	cosmetic	products,	detergents,	or	food	(the	
latter	includes	processing	at	home)	are	some	of	the	examples.4,15,16
3  | C AUSAL AGENTS
Agents	that	cause	allergic	WRA	and/or	allergic	occupational	rhinitis	en‐
compass	more	than	400	natural	agents	and	synthetic	chemicals.	They	
are	 listed	 in	textbooks,17	 review	articles3,18	and	websites	 (eg,	http://
www.eaaci.org;	 http://www.csst.qc.ca/en/preve	ntion/	repto	x/occup	
ation	al‐asthma; http://www.aoecd	ata.org/ExpCo	deLoo	kup.aspx).
Individual	publications	on	allergens	causing	occupational	asthma	
are	listed	in	the	Supporting	information	(see	Table	S1).
These	agents	are	categorized	into	high	molecular	weight	(HMW)	
and	 low	molecular	weight	 (LMW;	 <5	 kDa)	 agents.	 High	molecular	
weight	agents	are	proteins	of	animal,	vegetable,	or	microbial	origin	
acting	through	an	IgE‐mediated	mechanism.	Low	molecular	weight	
agents	include	organic	and	inorganic	compounds	that,	may	function	
as	 haptens	 and	with	 a	 few	 exceptions,	 are	 associated	with	 an	 IgE	
mechanism	in	a	proportion	of	affected	subjects.	Commonly	identi‐
fied	agents	of	OA	characterized	by	a	latency	period	between	initial	
exposure	and	asthmatic	symptoms	are	diisocyanates,	flour,	allergens	
from	 laboratory	 animals	 and	 insects,	 enzymes,	 colophony	 fluxes,	
solders,	 wood	 dusts,	 natural	 rubber	 latex,	 acrylates,	 and	 glutaral‐
dehyde.	Following	 sensitization,	workers	with	OA	may	develop	an	
asthmatic	attack	to	very	low	exposures	to	the	sensitizer.	The	extent	
of	 airway	 responsiveness	 may	 diminish	 away	 from	 exposure,	 but	
usually	increases	with	re‐exposure	to	the	sensitizer.
4  | DIAGNOSTIC ME A SUREMENT OF sIgE 
A S THE MA JOR STEP IN IDENTIF YING THE 
PRECISE C AUSE OF RESPIR ATORY ALLERGY
The	 practical	 division	 into	 HMW	 and	 those	 of	 LMW	 allergens	 is	
based	on	the	fact	that	LMW	substances	cannot	induce	an	IgE‐medi‐
ated	response	by	themselves;	rather	they	act	as	incomplete	antigens	
(or	haptens),	either	by	binding	to	host	proteins	or	as	reactive	agents	
forming	new	antigenic	sites	upon	reaction	with	host	molecules.19,20 
High	 molecular	 weight	 allergens	 are	 generally	 polypeptides,	 pro‐
teins,	or	glycoproteins	from	animals,	plants,	bacteria,	or	 fungi,	and	
often	have	a	molecular	weight	between	20	and	50	kDa.	Low	molecu‐
lar	weight	agents	are	usually	chemical	substances	with	mass	<5	kDa.
The	distinction	between	HMW	and	LMW	allergens	is	important	
when	performing	an	immunological	investigation.	It	is	relatively	easy	
to	 demonstrate	 an	 immune	 response	mediated	 by	 IgE	 in	 cases	 of	
HMW	agents	and	more	difficult	for	most	LMW	agents.	This	fact	has	
important	repercussions	in	terms	of	commercially	available	tests.
The	presence	of	allergen‐sIgE	can	be	investigated	by	in	vivo	skin	
tests	or	by	in	vitro	laboratory	tests.	The	procedures	are	briefly	dis‐
cussed	in	the	Supporting	information	(see	Diagnostic	measurement,	
page	S11).
Currently,	 laboratory	methods	for	the	detection	of	serum	anti‐
bodies	are	routine.	The	most	commonly	applied	techniques	are	the	
quantification	of	total	and	allergen‐specific	serum	IgE	(as	a	classical	
biomarker	 for	a	given	allergen).	These	procedures	have	 in	 spite	of	
some	limitation	a	number	of	advantages	over	the	skin	tests	because	
there	is	no	risk	to	the	patient,	the	results	are	not	influenced	by	drugs	
and	are	more	diagnostic	for	certain	groups	of	patients	such	as	pa‐
tients	with	dermographism	or	atopic	dermatitis.
Reaginic	 antibodies	were	 identified	 in	 the	 1960s	 as	 belonging	
to	a	new	immunoglobulin	class,	namely	IgE21	and	shortly	afterward	
the	radioallergosorbent	test	 (RAST)	was	developed.22	The	modern	
sIgE	assay	is	a	modification	of	the	RAST	assay;	using	the	same	basic	
three‐steps,	 solid	 phase,	 noncompetitive	 binding,	 immune‐metric	
(labeled	antibody)	chemistry,	combined	with	a	third	step,	that	is,	en‐
zyme‐substrate	 color,	 florescence,	 or	 luminescence	 development.	
Allergen‐sIgE	antibodies	are	bound	in	the	first	incubation	to	a	solid	
phase	allergen	and	then	bound	IgE	is	detected	in	a	second	reaction	
with	 labeled	anti‐human	 IgE.	The	magnitude	of	 the	response	after	
the	final	buffer	wash	is	proportional	to	the	quantity	of	allergen‐sIgE	
antibody	in	the	original	test	serum.	A	multipoint	total	IgE	serum	cal‐
ibration	curve	is	used	that	ranges	from	0.1	to	100	kUA/l	traceable	to	
the	World	Health	Organization	 human	 IgE	 reference	 preparations	
(note	WHO	recently	depleted	75/502	preparation	is	replaced	with	
third	 standard:	 11/234).	 This	 allows	 interpolation	 of	 IgE	 antibody	
results	 from	 any	 of	 the	 hundreds	 of	 allergen	 specificities	 as	 long	
as	the	allergen‐sIgE	portions	of	the	assay	dilute	out	in	parallel	with	
each	other.	Recently,	an	international	guidance	document	has	been	
published	on	the	analytical	performance	and	clinical	utility	of	human	
IgE.23	See	also	Supporting	information	(page	S18).
Currently,	 there	 are	 three	 singleplex	 auto	 analyzers	 that	 dom‐
inate	the	clinical	market	for	the	measurement	of	sIgE.23	These	are	
ImmunoCAP	(Thermo	Fisher	Scientific/	Phadia),	 Immulite	(Siemens	
Healthcare	Diagnostics)	and	HyTEC88	(Hycor	Biomedical,	which	 is	
being	 replaced	with	 Falcon).	Other	 IgE	 assays	with	 a	 limited	mar‐
ket	share	include	Thabest	IgE	(Visual	Diagnostics),	Optigen	(Hitachi	
Chemical	Diagnostics),	and	ALLERG‐O‐LIQ	(Fooke	laboratories).
Each	 of	 the	 principal	 auto	 analyzers	 has	 comparable	 perfor‐
mance	 parameters,	 which	 have	 to	 be	 described	 and	 cleared	 by	
regulatory	 agencies.	 These	 include	 excellent	 intra‐assay	 precision	
(typically	<	15%	coefficient	of	variance),	 inter‐assay	reproducibility	
(generally	<	20%	coefficient	of	variance),	a	limit	of	quantification	of	
0.1	kUA/l	and	a	reportable	assay	range	of	0.1‐100	kUA/l.23
Studies	 have	 compared	 the	 three	main	 sIgE	 assays	 and	 all	 re‐
ported	different	levels	of	IgE	antibody	for	any	given	specificity.24‐26 
This	 indicates	that	 it	 is	not	currently	possible	to	compare	sIgE	 lev‐
els	measured	using	different	sIgE	assays.	This	is	probably	due	to	the	
allergen	used	in	the	assay,	the	orientation	and	structural	modifica‐
tions	of	the	allergen,	and	differing	assay	protocols	including	the	solid	
phase	material,	slightly	different	assay	calibration,	and	data	compu‐
tation	procedures.27
Comparing	the	analytical	precision	and	accuracy	of	sIgE	assays,	
performed	in	different	laboratories	using	various	methods,	despite	
standardization	 to	 the	 WHO	 human	 IgE	 reference	 preparation,	
     |  1889BAUR et Al.
revealed	that	there	were	disparate	results	in	four	of	the	six	labora‐
tories.28	 This	 highlights	 the	need	 for	 laboratories	 to	 participate	 in	
quality	assurance	schemes	(eg,	CLIA,	ISO	17025)	and	to	make	those	
results	available	to	their	clients.
Historically,	 0.35	 kUA/l	 of	 allergen‐sIgE	was	 considered	 to	 be	
the	cutoff	point	where	an	individual	was	considered	as	a	threshold	
for	 positivity	 of	 the	 immunoassay,	 demonstrating	 sensitization.29 
The	current	recommendation	to	clinical	laboratories,	by	a	consensus	
guidance	document,23	is	that	sIgE	levels	must	be	reported	as	analyt‐
ical	measurements	down	to	the	cleared	limit	of	quantitation	of	the	
assays,	which	is	usually	0.1	kUA/l.	The	limit	of	quantitation	within	an	
assay	is	set	to	ensure	that	reported	low	quantitative	results	are	com‐
fortably	above	background	signal	(noise—chemical,	 instrument	and	
from	non–specific	IgE	binding).	Thus,	all	test	results	above	the	limit	
of	quantitation	should	be	regarded	as	true	allergen‐sIgE	antibodies.	
Historically,	sIgE	≥	0.35	kUA/l	was	considered	to	be	clinically	rele‐
vant,	however,	 it	 is	now	considered	that	clinicians	should	interpret	
IgE	 levels	 in	 the	context	of	 the	clinical	history,	 rather	 than	have	a	
defined	 cutoff	 point.29	 See	 Supporting	 information	 (page	 S18)	 for	
more	details.
It	 is	 important	 to	 understand	 that	 the	 presence	 of	 sIgE	 is	 an	
indicator	 of	 sensitization,	 it	 is	 not	 proof	 of	 allergic	 disease	 and	 is	
only	 clinically	 relevant	when	 there	 are	objectively	defined	 allergic	
symptoms	that	are	temporally	associated	with	a	known	allergen	ex‐
posure.27	A	positive	IgE	test	that	is	concordant	with	the	patient's	his‐
tory	and/or	a	challenge	test	confirms	“allergy”	to	a	particular	allergen	
and	can	be	used	as	confirmatory	evidence	of	sensitization	to	manage	
the	patient	 appropriately	 and	encourage	 improvement	of	environ‐
mental	control	measures	within	the	workplace.
4.1 | What is commercially available and suitable?
New	allergens	are	continually	being	identified	within	the	workplace,	
for	example,	horticultural	nematode,	Steinernema feltiae.30	The	list	of	
commercially	available	occupational	allergens	is	very	restricted,	for	
example,	Thermo	Fisher	(Phadia)	currently	has	only	36	ImmunoCAPs	
for	occupational	allergens,	although	they	do	also	provide	others	such	
as	animal	allergens,	for	example,	rat	and	mouse.	The	limited	availabil‐
ity	of	commercial	assays	for	the	measurement	of	sIgE	is	a	significant	
problem	within	the	field	of	occupational	allergy	and	asthma	that	ne‐
cessitates	the	use	of	“in‐house”	assays	to	measure	sIgE	to	noncom‐
mercially	available	allergens.
There	 are	many	 allergens	 and	 some	 components	 available	 for	
CAP	tests;	however,	there	are	only	a	limited	number	of	occupational	
HMW	allergen	components,	for	ImmunoCAP,	for	example,	there	are	
nine	recombinant	latex	allergens.	Availability	of	allergen	components	
has	led	to	improved	diagnosis	of	sensitization	in	some	cases.31‐34
4.2 | Occupational allergens are categorized as 
either high or low molecular weight
sIgE	assays	are	useful	to	demonstrate	IgE‐mediated	sensitization	to	
HMW	allergens	 (animal	 and	plant	 proteins)	 but	 less	 so	with	 LMW	
allergens,	which	are	predominantly	synthetic	chemicals.	Low	molec‐
ular	weight	allergens	are	too	small	to	be	recognized	by	the	immune	
system	without	conjugation	to	a	protein,	for	example,	human	serum	
albumin	(Table	1;	Figure	2;	Figure	3).
There	is	a	wide	spectrum	in	the	ability	to	detect	sIgE	for	LMW	al‐
lergens	ranging	from	the	possible	exception	of	acid	anhydrides	with	
relatively	high	detection	rates	(sensitivity	81%)	to	isocyanates	(sensi‐
tivity	21%;	specificity	94%)	and	plicatic	acid	(sensitivity	9.6%).33
Recent	studies	highlighted	the	difference	in	sIgE	binding	accord‐
ing	 to	 the	 conjugate	 preparation	 conditions.35,36	One	 of	 the	 diffi‐
culties	with	measuring	 sIgE	 to	 LMW	allergens	 (including	 products	
acting	 as	 haptens37,38)	 is	 that	 there	 are	 no	 standardized	 protocols	
for	the	preparation	of	protein‐LMW	allergen	conjugates	and,	char‐
acterization	of	 the	 resultant	 protein	hapten	 complex	 can	be	 tech‐
nically	challenging	and	complex.	There	were	various	approaches	to	
bind	LMW	agents	such	as	acid	anhydrides,7,39	glutaraldehyde,40 or 
isocyanates	 (for	more	details	 see	Table	 S2).	 The	diisocyanates	 are	
emblematic	of	difficulties	of	elucidating	underlying	antigenic	forms	
of	diisocyanate	haptenated	proteins.	Albumin	is	the	preferred	pro‐
tein	carrier,	but	multiple	proteins	are	potentially	haptenated	in	vivo	
(Figure	2).	Diisocyanates	have	been	reported	to	covalently	bind	to	
albumin,	 hemoglobin,	 lung	 epithelial	 proteins,	 tubulin,	 and	 kera‐
tins.41‐44	Proteomic	mass	spectrometric	studies	of	in	vitro	conjuga‐
tion	of	diisocyanate	to	albumin	and	hemoglobin	have	demonstrated	
that	diisocyanates	can	form	a	variety	of	complexes	with	proteins	in‐
cluding	inter‐	and	intramolecular	cross‐linked	species	(see	Figure	3).
There	has	been	a	debate	as	to	whether	the	low	sensitivity	of	sIgE	
assay	to	diisocyanates	may	in	part	be	due	to	heterogeneous	patho‐
mechanisms.	In	a	small	study	of	patients	with	a	clinical	diagnosis	of	
occupational	asthma	based	on	a	positive	bronchial	challenge,	there	
was	a	striking	absence	of	IL‐4	and	Cε	mRNA	observed	locally	within	
bronchial	mucosa	following	an	active	challenge,	which	is	in	contrast	
to	patients	with	asthma	to	high	molecular	weight	allergens	such	as	
grass	 pollen.45	 This	 suggests	 that	 in	 some	patients,	 isocyanate	 in‐
duced	 asthma	 may	 be	 a	 non‐IgE‐mediated	 disease.	 Confirming	
this	observation	in	serum	of	isocyanate	patients	with	occupational	
asthma	is	not	feasible	due	to	lack	of	a	reliable	validated	IL‐4	assay.46 
Studies	also	suggest	that	sIgE	against	plicatic	acid‐human	serum	al‐
bumin‐conjugate	 is	 unlikely	 to	be	 a	 causative	 factor	 in	 the	patho‐
mechanism	of	western	red	cedar	asthma,	suggesting	that	this	may	
also	be	a	non‐IgE‐mediated	disease,	at	least	in	some	patients.	Animal	
models	 of	 chemical‐induced	 asthma	 also	 suggest	 that	 IgE	mecha‐
nisms	are	not	necessary	to	elicit	respiratory	reactions	in	previously	
dermally	exposed	animals.47,48	Finding	sIgE	to	LMW	allergens	is	con‐
firmatory	of	sensitization,	but	a	negative	sIgE	does	not	rule	out	that	
agent	as	the	cause	of	a	WRA.
4.3 | In‐house sIgE tests
In‐house	assays	 are	 required,	 if	 no	 commercial	 tests,	 are	 available	
(ie,	 in	case	of	a	new	allergenic	protein).	 In	many	cases,	commercial	
tests	show	inconsistent	results,	though	clinical	data	clearly	points	to	
allergen‐related	symptoms	(showing	inconsistency	of	in	vivo	and	in	
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vitro	diagnostic	tests).49	sIgE	antibodies	are	generally	measured	with	
either	in‐house	fluorescence	enzyme	labeled	immunoassay	using	bi‐
otinylated	protein	coupled	to	streptavidin	CAPs,	in‐house	ELISAs,	or	
in‐house	immunoblots.
There	is	a	need	for	establishment	of	a	publicly	funded	laboratory	
working	with	this	sophisticated	in‐house	sIgE	issue.	For	more	details	
see	additional	Supporting	information.
4.4 | The need for assay standardization
At	present	there	are	no	standard	operating	procedures	for	conduct‐
ing	“in‐house”	assays.33	Current	FDA	guidance	regulations,	regard‐
ing	 fluorescence	 enzyme	 labeled	 immune‐assay	 based	 methods,	
state	that	 the	source	and	stability	of	allergen‐specific	control	sera	
should	be	specified.	It	is,	however,	to	be	emphasized	that	all	immu‐
nological	methods	 (in‐house	and	commercial)	have	 to	be	validated	
routinely	with	 control	 serum	 samples	 and	 additional	 standard	 set	
points	(two	analytic	standards,	one	with	low	concentration	and	the	
other	with	high	concentration,	are	used	as	set	points).4	For	valida‐
tion	of	the	assays,	a	minimum	of	the	following	controls	need	to	be	
included:	tests	with	pooled	sera	from	sensitized	and	nonsensitized	
subjects,	biotin	and	HSA‐control	samples.	The	measured	day‐to‐day	
precision	and	variability	in	series	measurements	should	follow	good	
laboratory	practice	rules.
For	 further	 details,	 techniques,	 and	 analyses	 of	mediators	 see	
Supporting	information.
Exposure	assessment
Standard	chemical	air	sampling	and	analysis	methods	exist	for	
many	of	the	low	molecular	weight	allergens,	however,	in	many	
cases	exposure	to	these	electrophilic	chemicals	is	not	just	to	the	
monomeric	form.	Exposure	can	be	to	a	mixture	of	monomers,	
polymers	and	prepolymeric	forms,	but	analytical	methods	are	
mainly	only	for	monitoring	the	monomeric	forms
Exposure	assessment	for	characterizing	levels	leading	to	immuno‐
logical	sensitization	(vs.	asthma	elicitation)	is	extremely	difficult	
and	in	general	lacking.	This	includes	both	respiratory	and	dermal	
sensitizing	events
Biomarkers	of	exposure	have	been	reported	(especially	for	LMW	
allergens)	in	the	literature,	(eg,	allergen	metabolites	or	adducts),	
but	they	have	not	always	been	used	as	an	exposure	monitoring	
tool
Exposure	monitoring	for	high	molecular	weight	allergens	may	
entail	measurement	of	multiple	allergenic	proteins,	especially	
from	natural	products.	The	specific	aeroallergen(s)	responsible	
for	disease	may	vary	with	the	life	cycle	of	that	product
Quantitative	dermal	exposure	assessment	methods	are	lacking,	
which	hinders	the	assessment	of	the	level	of	dermal	sensitization	
in	subsequent	asthma	development
Early	biomarkers	of	allergic	sensitization,	in	addition	to	specific	
IgE	are	needed	to	prevent	subsequent	asthma	development
Direct	reading	instruments	with	sufficient	sensitivity	are	needed	
to	monitor	relevant	worker	exposure	to	agents	known	to	cause	
occupational	asthma
TA B L E  2   (Continued)TA B L E  1  Statements
Diagnostics
The	occupational	type	1	allergy	of	greatest	concern	is	occupa‐
tional	asthma;	exposure‐related	type	1	allergic	rhinitis,	conjunc‐
tivitis,	and	protein	contact	dermatitis	also	play	a	role
The	diagnoses	of	occupational	type	1	respiratory	allergies	follows	
an	algorithm	approach,	starting	with	clinical	and	qualified	oc‐
cupational	history,	followed	by	confirmation	of	the	disease	with	
objective	methods	and	allergy	testing	(SPT	test	or	sIgE	measure‐
ment),	and,	if	needed,	spirometry	monitoring	during	work	shifts	
or	specific	nasal	challenge	or	SIC
Commercial	sIgE	tests	generally	lack	transparent	information	on	
the	allergen	preparation	used,	applied	standardization	and	qual‐
ity	control
In‐house	tests	mostly	do	not	follow	appropriate	standardization	
and	quality	control;	they	differ	from	place	to	place	considerably	
and	do	not	allow	comparison	of	the	results	definitively
There	are	limited	commercial	occupational	allergens	available	
on	CAP.	This	necessitates	specialized	laboratories	to	provide	
bespoke	“in‐house”	assays	for	novel	putative	and	allergens	which	
are	not	available	on	CAP
Negative	results	from	a	bespoke	in‐house	assay	for	putative	novel	
allergens	do	not	necessarily	imply	a	negative	test,	if	there	are	no	
positive	controls.	sIgE	tests	are	only	as	good	as	the	composition	
of	the	allergens	used	in	the	assay.	Thus,	we	need	to	ensure	that	
for	any	sIgE	measurement,	we	use	the	appropriate	allergens
The	laboratory	should	always	assess	the	performance	of	sIgE	
assay	by	carrying	out	a	clinical	audit.	The	performance	of	any	
sIgE	test,	whether	it	is	RAST	or	CAP,	is	very	dependent	on	al‐
lergen	used	and	the	positive	cut	off	value
CAP,	RAST,	and	other	methods	for	measurement	of	sIgE	can	give	
similar	sensitivity	to	skin	prick	test	when	the	same	allergen	is	
used	for	both	test,	for	example,	95%	for	protease	and	cellulase,	
98%	for	amylase,	99%	rat	urine
sIgE	to	HMW	allergens	provide	acceptable	sensitivity	and	speci‐
ficity	and	are	very	useful	as	a	diagnostic	test
Specific	IgE	assays	to	LMW	allergens	are	more	problematic	and	
dependent	on	the	allergen	investigated.	sIgE	measurement	to	
isocyanates	is	specific	but	not	sensitive,	whereas	sIgE	to	acid	an‐
hydride	could	have	acceptable	sensitivity	and	specificity,	which	
needs	to	be	assessed	with	larger	cohorts.	To	date,	we	are	unable	
to	measure	sIgE	for	platinum	salts.	Thus	each	low	molecular	
weight	allergen	must	be	considered	case	by	case
By	use	of	sIgE	tests	HMW	allergens	provide	acceptable	sensitivity	
and	specificity	mostly	above	0.7	kUA/l.	This	is	especially	shown	
for	extracts	from	cereals,	latex,	enzymes,	bovine	epithelium	and	
bovine	dander,	molds,	insects,	and	for	particular	approaches	with	
recombinant	allergen	components
Some	wood	extracts	and	LMW	agents	such	as	diisocyanates,	acid	
anhydrides	provide	much	lower	sensitivity	than	confirmed	HMW	
allergens;	obviously,	this	is	at	least	in	part	due	to	heterogenous	
patho‐mechanisms	including	irritant	effects
Prevention
Early	diagnosis	of	respiratory	allergies	combined	with	avoidance	
of	the	causative	allergen	is	important	because	it	prevents	the	al‐
lergy	march	from	rhinitis	to	asthma,	as	well	as	chronification	and	
deterioration	of	the	disorders
(Continues)
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4.5 | Early biomarkers of allergic sensitization, 
mediators, and cellular tests used in diagnostics
Allergy	is	an	immune	mediated,	inflammatory	response	involving	dif‐
ferent	types	of	cells	that	release	a	multitude	of	inflammatory	media‐
tors.50	The	mast	cells	act	as	effector	cells	releasing	mediators	such	
as	histamine	and	tryptase	among	others	upon	antigen‐	and	IgE‐de‐
pendent	 activation,	 but	 also	by	 several	 other	mechanisms.	During	
cell	activation,	eosinophils	secrete	eosinophil	cationic	protein	(ECP),	
while	basophils	release	the	content	of	their	granules	after	a	process	
of	activation	dependent	on	the	antigen.
For	diagnostic	details	see	the	Supporting	information.
5  | OUTCOME OF THE META‐ANALYSIS 
AND RE VIE W PERTINENT QUESTIONS
5.1 | What are the sIgE test performances for high 
molecular weight allergens?
The	 aforementioned	 meta‐analysis	 of	 studies	 including	 asthmatic	
subjects	exposed	to	various	occupational	HMW	agents	found	that	
specific	 IgE	 determination	 provided	 a	 sensitivity	 of	 74%	 [95%	 CI	
66%‐80%],	as	compared	with	specific	inhalation	challenge	or	serial	
peak	 flow	measurements,	while	 the	 specificity	 of	 these	 tests	was	
71%	[95%	CI	63%‐77%].33	The	results	are	in	the	range	of	a	previous	
analysis	based	on	fewer	studies.51
Sensitivity,	specificity,	positive	predictive	value	(PPV),	and	nega‐
tive	predictive	value	(NPV)	for	a	cohort	of	bakers	were	calculated	at	
a	cutoff	value	of	0.35	kUA/l	for	wheat	and	rye	flour	sIgE.	Specificity	
was	68%	and	62%,	PPV	74%	and	82%	and	NPV	was	82%	and	71%,	
respectively,	whereas	sensitivity	was	87%	for	each	of	these	flours.52
For	natural	 rubber	 latex	 (NRL),	 the	 sensitivity,	 specificity,	PPV,	
and	NPV	of	a	sIgE	level	≥	0.35	kUA/l	as	compared	to	the	result	of	
SICs	were	94%,	48%,	86%,	and	71%,	respectively.31
Results	of	our	new	meta‐analysis	for	sensitivities	of	single	HMW	
allergens	 ranged	 from	 72%	 [95%	 CI	 42%‐90%]	 for	 cellulase,	 0.79	
[95%	CI	65%‐88%]	for	wheat,	0.84	[95%	CI	65%‐94%]	for	rye	to	0.88	
[95%	CI	42%‐99%]	for	latex.33
5.2 | What are the test performances for allergenic 
components?
Using	commercial	ImmunoCAP	analysis,	sensitization	to	green	coffee	
beans	was	found	 in	2/18	 (11%)	of	workers	with	symptoms	of	aller‐
gic	 rhinitis	and/or	conjunctivitis	under	coffee	dust	exposure.	ELISA	
screening	showed	sIgE	reactivity	to	rCof	a	1,	rCof	a	2,	and	rCof	a	3	
in	a	total	of	8	out	of	18	(44%)	sera	of	symptomatic	coffee	workers.53
The	specificity	of	measuring	sIgE	to	a	panel	of	Triticum aestivum 
components,	(Tri	a)	27,	28,	29.02,	32,	and	39	was	97%	with	a	sensi‐
tivity	of	70%	for	wheat	flour	allergy	among	bakers.54
Twenty‐one	(48.8%)	of	the	43	sera	with	negative	results	to	com‐
mercial	wheat	flour	ImmunoCAP	(f4)	yielded	positive	results,	with	at	
least	1	of	6	newly	identified	wheat	recombinant	proteins.55
However,	for	routine	diagnosis	of	baker's	allergy,	allergen‐sIgE	
tests	with	whole	wheat	and	rye	flour	extracts	were	shown	to	be	of	
superior	diagnostic	sensitivity,	when	compared	to	components.54
Vandenplas	 et	 al31	 found	 that	 the	 sum	 of	 sIgE	 concentrations	
against	the	recombinant	allergens	of	Hevea brasiliensis	(rHev	b5)	and	
F I G U R E  2  Chemical	haptenation	of	albumin	upon	dermal	exposure	to	diisocyanate	(from	Hettick	and	Spiegel,	International	Journal	of	
Mass	Spectrometry	309,	168‐75,	2017).	The	figure	displays	diisocyanate	haptenation	sites	on	human	serum	albumin	(left	=	MDI,	right	=	TDI).	
Electrophilic	chemical	allergens	can	bind	to	multiple	nucleophilic	sites	on	self‐proteins.	Diisocyanates	can	also	self‐polymerize,	thus	
multiple	potential	neo‐antigens	may	be	produced	following	chemical	exposure.	Left:	serum	albumin	Lys	residues	haptenated	by	MDI.	Right:	
serum	albumin	Lys	residues	haptenated	by	TDI.	Serum	albumin	and	skin	keratins	have	been	identified	by	mass	spectrometry	as	targets	of	
haptenation	upon	dermal	exposure.	Which	residues	are	haptenated	depends	on:	Identity	of	the	isocyanate	(electrophilic	reactivity	and	
size);	Accessibility	of	the	site	(sterics);	Chemical	composition	of	the	residue	(primary	amines);	pH	of	the	microenvironment	and/or	pKa	of	the	
sidechain	(‐NH2	reactive,	not−NH+
3
);	Concentration	of	the	isocyanate	(less	kinetically	favorable	observerd	at	higher	concentration).	“Dilysine”	
motifs	are	preferred	conjugation	sites	in	vitro	and	in	vivo:	Lys413‐Lys414	and	Lys524‐525	of	serum	albumin	are	conjugated	in	skin	and	lung	
of	mouse	model;	These	sequence	motifs	are	conserved	in	humans;	Enhanced	reactivity	most	likely	due	to	suppressed	pKa	of	second	Lys	
residue.	For more information, see: Hettick, J et al Xenobiotica. 2017 Jul 21:1‐11; Nayak, A et al Toxicol Sci. 2014 Aug 1;140(2):327‐37; Hettick, J et 
al Anal Biochem. 2012 Feb 15;421(2):706‐11; Wisnewski, A et al Anal Biochem. 2010 May 15;400(2):251‐8
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r	Hev	 b	 6.01	 or	 6.02	 yielded	 a	 higher	 predictive	 value	 (>95%)	 for	
positive	SIC	similar	to	that	provided	by	the	level	of	sIgE	against	the	
whole	latex	extract,	but	with	higher	sensitivity	(79%)	and	diagnostic	
efficiency	(0.67)	as	compared	with	whole	latex‐sIgE	(49%	and	0.41,	
respectively).	 Combining	 positive	 sIgE	 results	 for	 the	NRL	 extract	
and	the	recombinant	allergen	components	rHev	b	5,	6.01,	6.02,	and	
11	provided	similar	AUC	(0.84‐0.85)	and	Youden	 index	 (0.61‐0.65)	
values	 (data	not	detailed),	but	did	not	 improve	 the	diagnostic	per‐
formance.	 Nevertheless,	 measurement	 of	 sIgE	 antibodies	 against	
the	tested	panel	of	recombinant	latex	allergen	components	did	not	
improve	 the	negative	predictive	value	of	 immunological	 testing	as	
none	of	the	subjects	with	positive	SIC	and	a	negative	IgE	against	the	
whole	latex	extract	showed	IgE	reactivity	to	allergen	components.
Supplementation	 of	 natural	 extracts	 with	 recombinant	 com‐
ponents	 (“spiking”)	has	already	entered	daily	practice	 in	the	field	of	
occupational	allergy	 laboratory	analyses.	Latex	component	Hev	b	5	
added	to	the	natural	extract	raised	sensitivity	from	76%	to	90%	with‐
out	lowering	specificity.	The	method	became	commercially	available	
with	a	CAP	test.56
5.3 | What are the sIgE test performances for low 
molecular weight allergens?
For	LMW	the	preparation	conditions	can	greatly	affect	the	degree	
of	 haptenation	 and	 test	 performance.	 There	 are	 no	well	 accepted	
standard	methods	for	reacting	LMW	agents	to	albumin,	or	for	char‐
acterizing	the	resultant	haptenated	protein.
Lux	et	al33	reported	a	sensitivity	of	28%	[95%	CI	18%‐40%]	with	
a	 specificity	 of	 89%	 [95%	 CI	 77%‐95%]	 for	 occupational	 asthma	
caused	by	various	LMW	allergens.	 In	a	previous	publication	with	a	
smaller	study	group,	similar	data	with	sensitivity	of	31%	and	speci‐
ficity	of	97%	were	reported.51
Elevated	 sIgE	by	 the	ELISA	method	 to	diisocyanate	 conjugated	
with	human	serum	albumin	had	a	sensitivity	of	31%	and	a	specificity	
of	97%,	in	bronchial	provocation	test	positive	patients.57	Tee	et	al58 
reported	a	sensitivity	of	28%	and	a	specificity	of	92%	with	a	RAST	
ratio	cutoff	point	of	2.0	in	patients	who	had	a	positive	bronchial	chal‐
lenge	test	to	isocyanates.	Baur	found	a	sensitivity	of	14%,59	and	later	
20%	with	 comparable	 specificity	 (personal	 communication).	Meta‐
analysis	provided	21%	[95%	CI	14%‐31%]	and	94%	[95%	CI	88%‐97%])	
for	pooled	pairs	of	 sensitivity	and	specificity.33	Pooled	sensitivities	
of	 single	 diisocyanates	HDI,	 TDI,	 and	HDI	 ranged	 from	 21%‐42%.	
Sensitivity	for	acid	anhydrides	was	exceptionally	high	with	81%	[95%	
CI	46%‐95%],	but	the	estimation	was	based	on	few	results33.
6  | ALLERGEN E XPOSURE A SSESSMENT
An	 important	 aspect	 in	 the	management	 and	 diagnosis	 of	 type	 1	
allergic	 disorders	 is	 the	 knowledge	 of	 the	 environmental	 levels	 of	
F I G U R E  3   Immunochemical	co‐
localization	in	mouse	skin	of	2,4‐TDI	
haptenated	proteins	(albumin,	and	
cuticular	and	cytoskeletal	keratins)	along	
with	antigen	presenting	cells	(from:	Nayak	
et	al	Tox	Sci:	140(2)	327‐337,	2014).	
Dermal	LMW	chemical	sensitization	is	
often	used	with	subsequent	respiratory	
challenge	to	model	LMW	chemical	
asthma.	TDI	was	observed	to	rapidly	
haptenate	dermal	proteins,	especially	
in	the	outer	root	sheath	of	the	hair	
follicle,	and	recruit	antigen‐presenting	
cells	(CD11b	APCs,	CD207	Langerhans	
cells	and	CD103+CD207+	Langerhans	
cells)	with	subsequent	transport	to	
local	draining	lymph	nodes.	Confocal	
microscopic	images	of	Langerhans	cells	
(top	left),	TDI	haptenated	tissue	(top	
right),	cell	nuclei	(bottom	left)	and	overlay	
of	Langerhans	cells,	nuclei,	and	TDI	
haptenated	tissue	(bottom	right)
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antigens.	This	 involves	an	understanding	of	 the	 total	 environment	
including	both	the	external	environment	and	also	the	interior	of	the	
houses	or	work	areas.	The	quantification	of	substances	in	the	envi‐
ronment	has	various	applications	that	can	be	of	help	in	the	diagnosis	
of	 these	 disorders.	 Quantitative	 and	 qualitative	measures	 of	 past	
and	present	allergen	exposure	are	especially	important	in	identify‐
ing	the	sensitizing	agent(s),	to	estimate	dose	response	relationships	
and	 for	preventing	 the	elicitation	of	asthmatic	episodes.	Exposure	
assessment	can	be	multifaceted	including	the	use	of	questionnaires,	
job	exposure	matrices,	direct	 sampling	of	 the	air	 and	on	 skin,	 and	
biomonitoring.
6.1 | Air sampling methods and databases
Heederik	 et	 al60	 thoroughly	 addressed	 the	 topic	 of	workplace	 ex‐
posure	 sampling,	 analyses,	 assessment	 strategies,	 and	 data	 inter‐
pretation.	 For	 asthma,	 inhalable	 dust	 sampling	 is	 most	 commonly	
measured	and	recommended	in	order	to	collect	the	portion	of	the	
aerosol	that	can	be	inhaled	by	the	worker	and	deposited	in	any	part	
of	the	respiratory	tract	(see	Supporting	information,	Figure	S1).
For	air	monitoring	to	allergens,	it	is	important	to	consider	that	
generally	HMW	allergen	and	many	LMW	exposures	occur	in	the	
workplace	as	dust	or	aerosols	(the	latter	may	also	occur	as	vapors)	
which	 dictates	 the	 type	 of	 corresponding	 sampling	 procedures.	
Established	and	validated	procedures	for	the	sampling	of	dust	are	
available	from	NIOSH,	the	MAK	commission,	and	other	working	
groups	(NIOSH	Manual	of	Analytical	Methods	5th	edition61;	the	
MAK‐Collection	for	Occupational	Health	and	Safety	Part	 III:	Air	
Monitoring	Methods	(DFG).62	Further	collection	of	air	monitoring	
methods	is	provided	by	the	Health	and	Safety	Executive	(UK)63: 
In	 the	 United	 States,	 the	 National	 Institute	 for	 Occupational	
Safety	and	Health's	Manual	of	Analytical	Methods	 (NMAM;	4th	
and	5th	addition)	is	available	on	line	https://www.cdc.gov/niosh/
docs/2003‐154/default.html;	https://www.cdc.gov/niosh/nmam/
default.html.61	In	addition	to	specific	methods,	guidance	chapters	
are	available	in	the	NMAM	to	assist	in	developing	sampling	strat‐
egies	and	methods	development.	Particularly,	the	following	chap‐
ters	of	the	NIOSH	Manual	of	Analytical	Methods	may	be	helpful	
as	 guiding	 documents:	 Purpose	 and	 Scope,	 Development	 and	
Evaluation	 of	 Methods,	 Measurement	 Uncertainty	 and	 NIOSH	
Method	 Accuracy	 Range,	 General	 Considerations	 for	 Sampling	
Airborne	 Contaminants,	 Factors	 Affecting	 Aerosol	 Sampling,	
Sampling	and	Characterization	of	Bioaerosols,	Filter	Pore	Size	and	
Aerosol	Sample	Collection,	Measurement	of	Fibers,	and	Sampling	
F I G U R E  4  Diagnostic	approach	in	case	
of	suspected	occupational	(environmental‐
related)	asthma.	For	details	see	text	in	
the	Supporting	information.	*Please	note	
that	there	are	rare	cases	of	work‐related	
asthma	without	NSBHR	or	absence	of	
an	obstructive	ventilation	pattern	during	
work.	If	the	case	history	is	supportive	
of	work‐related	asthma	additional	
(facultative)	diagnostics	is	recommended	
as	indicated	in	Figure	4.	It	should	be	taken	
into	consideration	that	false‐negative	
outcomes	of	the	NSBHR	test,	spirometric	
monitoring	and	the	SIC	test	may	occur	
due	to	medication	or	latency	periods	of	
several	weeks	or	more	since	last	exposure.	
The	SIC	may	also	be	false	negative	if	not	
perfored	with	the	correct	agent.	If	this	has	
to	be	assumed	in	a	case	whose	history	is	
strongly	supportive	of	asthma,	repetition	
of	the	individual	diagnostic	tests	has	to	be	
considered
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and	 Analysis	 of	 Soluble	 Metal	 Compounds.	 The	 Occupational	
Safety	and	Health	Administration	(OHSA)	has	a	similar	database	at	 
https	://www.osha.gov/dts/sltc/metho	ds/index.html.	While	these	
databases	are	not	specific	for	chemicals	that	cause	asthma,	they	
contain	 many	 methods	 for	 the	 more	 common	 ones.	 Methods	
TA B L E  2  Recommendations
General	diagnostic	aspects
Diagnostics	of	respiratory	and	skin	type	1	disorders	should	start	
with	a	qualified	clinical	and	occupational	case	history,	followed	
by	non‐	or	less‐invasive	methods,	that	is,	clinical	status,	func‐
tional,	and	allergy	tests	(prick	and/or	sIgE)	and	finally,	if	needed	
for	prevention	or	therapy,	by	serial	lung	function	measurement	
and/or	specific	nasal	challenge	or	SIC
In	case	of	suspected	allergic	OA,	but	unclear	diagnostic	findings,	
serial	lung	function	measurement	according	to	standardized	
protocol	(2	weeks	work,	2	weeks	off	work)	are	recommended.	
SIC	is	only	recommended	in	suspected	occupational	asthma	
cases	if	serial	lung	function	measurement	is	not	possible	and	all	
diagnostic	tests	do	not	provide	a	clear	diagnosis	but	diagnosis	is	
needed	for	far‐reaching	preventive	or	therapeutic	measures
Measurement	of	sIgE	to	suspected	causative	environmental	al‐
lergens	by	use	of	a	standardized	specific	and	sensitive	method	
is	recommended	within	the	diagnostic	setup	in	order	to	identify	
the	causative	agent
The	manufacturers	of	commercial	sIgE	are	requested	to	provide	
full	transparency	of	the	allergen	preparations	they	use	along	
with	details	of	standardization	and	quality	control
For	in‐house	sIgE	assays	there	should	be	standard	operating	pro‐
cedures	which	should	include	batch	to	characterization	of	aller‐
gen	for	in‐house	s	IgE	assays	(including	measurement	of	protein	
content,	electrophoresis	and	immunoblotting).	Development	of	
assay	should	include	testing	of	at	least	20	negative	sera	of	sub‐
jects	not	exposed	to	individual	allergen	(however,	their	total	IgE	
should	cover	a	range	up	to	1000	IU/ml)	and	at	least	three	sera	of	
subjects	suffering	from	IgE	sensitization.	The	sIgE	assay	should	
be	standardized	against	the	gold	standard	3rd	World	Health	
Organization	(WHO)	International	Reference	Reagent	(IRR)	for	
serum	IgE	(75/502;5000	IU/ampoule).	(Note:	this	may	be	difficult	
for	putative	novel	allergens).	http://www.who.int/biolo	gical	s/
BS_2220_Candi	date_Prepa	ration.pdf
There	is	a	need	for	specialized	laboratories	to	provide	a	bespoke	
service	for	the	measurement	of	putative	novel	occupational	al‐
lergens	and	also	those	allergens	not	available	commercially
Determination	of	sIgE	to	high	molecular	weight	allergens	is	
recommended	as	a	valuable	diagnostic	tool	within	the	diagnostic	
setup	algorithm	in	bronchial	asthma
The	presence	of	sIgE	to	low	molecular	weight	agents	such	as	
diisocyanates	and	acid	anhydrides	should	be	regarded	as	strong	
evidence	for	relevant	sensitization,	whereas	negative	sIgE	must	
be	regarded	with	caution	due	to	frequent	false	negative	results
Laboratories	should	always	carry	out	clinical	audits	(systematic	
and	independent	examination	whether	processes,	requirements	
and	rules	meet	required	standards)	on	their	sIgE	assays	which	
will	determine	whether	commercially	available	assays	or	“in‐
house”	assay	provides	the	best	diagnostic	specific	IgE	assay
Commercially	available	sIgE	assays	can	be	recommended	for	most	
allergens	(although	there	are	exceptions	eg,	acid	anhydride,	iso‐
cyanates)	as	a	standardized	method	to	measure	sIgE;	however,	
its	relatively	high	costs	have	to	be	considered	and	limit	its	broad	
application
Nasal	diagnostic	aspects
The	diagnosis	of	allergic	rhinitis	including	occupational	rhinitis	is	
based	on	history,	clinical	findings	and	confirmation	by	sIgE	to	
relevant	allergens
(Continues)
The	nasal	endoscopy	is	indicated	to	evaluate	anatomical	or	infec‐
tious	diseases
The	nasal	challenge	test	is	recommended	to	diagnose	allergic	
rhinitis,	local	allergic	rhinitis,	nasal	hyperreactivity,	or	occupa‐
tional	rhinitis
Specific	nasal	allergen	challenges	should	be	performed	accord‐
ing	to	the	standardized	protocol	of	the	recently	published	
EAACI	Position	paper	65Diagnostic	tests	such	as	assessment	of	
nonspecific	nasal	hyperresponsiveness	or	specific	nasal	allergen	
challenges	are	a	key	aspect	of	specialized	clinical	centers
Skin	testing
Patients	suspected	to	suffer	from	immediate‐type	allergy	to	
occupational/environmental	allergens	should	be	appropriately	
screened	for	possibly	causative	agents,	and,	where	possible,	
discontinued	on	medications	that	interfere	with	test	results,	
accentuate	systemic	allergic	reactions	or	render	patients	less	
responsive	to	treatment	with	epinephrine.
Even	though	SPT	is	safe	with	no	reported	fatalities,	a	physician	or	
other	healthcare	professional	and	emergency	equipment	should	
be	immediately	available	when	such	tests	are	performed
SPT	should	be	performed	with	extra	caution	during	the	respective	
allergy	season	when	the	patient	has	allergic	symptoms,	or	when	
baseline	tryptase	levels	are	elevated.66,67	The	latter	is	a	risk	fac‐
tor	for	anaphylaxis	and	mastocytosis
Relative	contraindications	for	SPT	include	pregnancy,	in	view	of	
a	remote	possibility	of	inducing	a	systemic	allergic	reaction	that	
could	induce	uterine	contractions	or	necessitate	the	use	of	epi‐
nephrine	(thought	to	cause	constriction	of	the	umbilical	artery
SPTs	are	difficult	to	perform	or	to	interpret	in	patients	with	severe	
eczema,	dermographism,	or	who	are	taking	antihistamines	or	
other	medications	such	as	certain	antidepressants	or	calcineurin	
inhibitors
The	degree	of	skin	test	reactivity	can	be	decreased	in	sub‐
jects	with	chronic	illnesses	such	as	renal	failure,	or	cancer.	
Furthermore,	chronic	or	acute	UV‐B	radiation	of	the	skin	in	the	
test	area	may	reduce	the	wheal	size	from	SPT
It	is	difficult	or	impossible	to	develop	stable	test	extracts	for	
certain	allergens,	in	particular,	certain	foods,	for	example,	for	
skin	testing	to	uncooked	fruits	and	vegetables.	A	prick‐to‐prick	
technique	is	utilized,	that	is,	first	pricking	the	fresh	food	with	
the	lancet	and	then	pricking	the	skin,	to	test	for	sensitization	to	
such	allergens	when	clinical	allergy	is	suspected,	in	particular,	
oral	allergy	syndrome.	Dry	foods,	for	example,	nuts	or	cereal,	
can	be	tested	in	saline	and	also	utilized	using	the	prick‐to‐prick	
technique
Exposure	assessment
	“At‐risk”	worksites	exposure	monitoring	of	the	specific	allergenic	
components	should	be	routinely	conducted	and	employ	direct	
reading	continuous	(personal)	monitors	whenever	possible
Biomarkers	of	exposure	should	be	standardized	and	used	to	sup‐
plement	environmental	monitoring
TA B L E  2   (Continued)
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harmonization	 for	 occupational	 exposure	 monitoring	 among	
stakeholders	 including	government	entities	and	consensus	stan‐
dard	organizations	is	recognized	as	important	in	“leveraging	cur‐
rent	and	future	applied	research,	as	well	as	 technology	transfer	
endeavors,	within	the	discipline	of	occupational	hygiene	chemical	
and	biochemical	sampling	and	analysis.”64	Assessing	exposure	to	
low molecular weight agents is mostly performed with help of ambi‐
ent‐ and biomonitoring methods.60
For	details	see60	and	Supporting	information	(page	S23).
7  | INTEGR ATED DIAGNOSTIC 
APPROACH FOR OCCUPATIONAL AND 
ENVIRONMENTAL INDUSTRIAL ALLERGENS
Details	are	given	in	Figure	4	and	in	the	Figure	S2.
8  | STATEMENTS AND 
RECOMMENDATIONS
Based	on	the	aforementioned	data	and	results,	we	make	the	follow‐
ing	statements	and	recommendations	(Table	1,	Table	2).
It	 is	 important	 that	 manufacturers	 of	 commercially	 available	
sIgE	tests	communicate	their	data	on	diagnostic	allergen	prepara‐
tion,	standardization,	quality	control,	including	background	defini‐
tion,	and	inform	whether	their	method	provides	quantitative	results	
by	 referring	 to	 the	WHO	 IgE	 standard.	Development	of	 in‐house	
methods	for	sIgE	testing	necessitates	expertise	with	such	methods	
and	is	rather	expensive	and	laborious.	It	would	be	helpful	if	in‐house	
assays	could	aspire	to	 	aforementioned	prerequisites	for	commer‐
cially	available	tests,	although	in	reality	 it	 is	difficult	to	be	able	to	
include	a	WHO	IgE	standard	reference.	Regarding	diagnostics	we	
also	stress	exposure	assessment	by	a	questionnaire	combined	with	
measurement	of	the	allergen	load	in	the	specific	environment;	this	
allows	 the	 risk	 of	 allergic	 disorders	 to	 be	 estimated.	 Surveillance	
of	high	 risk	 subjects	 (eg,	 those	with	high	 level	of	 sIgE	antibodies)	
and	individuals	in	“at‐risk”	sites,	especially	workplaces,	are	recom‐
mended	 in	order	 to	 take	appropriate	preventive	measures	and	 to	
optimize	medication.
For	a	broader	view	of	this	items	see	Supporting	information,	sec‐
tion	Points to be emphasized and prospective.
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